UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 4, 2014
Minerva Neurosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-36517 | | 26-0784194 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
245 First Street | | | |
Suite 1800 | | | |
Cambridge, MA | | | 02142 |
(Address of principal executive offices) | | | (Zip Code) |
(Registrant’s telephone number, including area code): (617) 444-8444
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
Minerva Neurosciences, Inc. (the “Company”) is presenting at the Baird 2014 Health Care Conference on Thursday, September 4, 2014 in New York City, New York. The materials that the Company intends to utilize in the presentation are furnished as Exhibit 99.1 to this current report and incorporated herein by reference.
The Company expressly disclaims any obligation to update this presentation and cautions that it is only accurate on the date it was presented. The inclusion of any data or statements in this presentation does not signify that the information is considered material.
This information contained or incorporated herein, including the presentation furnished as Exhibit 99.1, is being furnished, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit
No. | | Description |
| 99.1 | | Presentation of the Company dated September 4, 2014 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | MINERVA NEUROSCIENCES, INC. |
| | | |
| | | |
Date: | September 4, 2014 | | By: | /s/ Rogerio Vivaldi Coelho MD, MBA |
| | | | |
| | Name: | Rogerio Vivaldi Coelho MD, MBA |
| | Title: | President, Chief Executive Officer and Director |
3
EXHIBIT INDEX
Exhibit | | Description |
99.1 | | Presentation of the Company dated September 4, 2014 |
4
